“We Are Not That Great.” Gain-of-Function Research Highlights Our Hubris

Humanity has a remarkable talent for building tools before fully understanding the hands that will hold them. We split atoms, mapped genomes, trained machines to write poetry, and learned how to edit life with a precision that would make a science-fiction author spill coffee on their keyboard. Then, every so often, reality taps us on the shoulder and says, “Cute. Now explain your safety plan.”

Gain-of-function research sits right in the middle of that uncomfortable conversation. In simple terms, gain-of-function research involves changing an organism so it gains a new ability or an enhanced trait. Most of the time, that phrase covers ordinary, useful biology. Scientists might alter a microbe so it produces insulin, test how a virus interacts with immune cells, or study how mutations affect disease. But when the organism is a dangerous pathogenor could become onethe phrase becomes heavier. It begins to raise questions about biosafety, biosecurity, public trust, and the old human habit of assuming that because we can do something, we probably should.

The title quote, “We are not that great,” is not anti-science. It is pro-humility. It is a reminder that science is powerful, but scientists are human. Institutions are human. Funding systems are human. Oversight committees are human. Humans mislabel samples, misunderstand incentives, forget passwords, skip steps, defend reputations, and occasionally build systems so complicated that nobody knows who is truly accountable. That is not cynicism. That is Tuesday.

What Gain-of-Function Research Really Means

Gain-of-function research is often discussed as if it were one scary category, but that is too simple. In biology, “gain of function” can mean a broad range of experiments where an organism, cell, or molecule gains a new property. Some of these studies are routine and low-risk. Others deserve intense scrutiny because they could increase a pathogen’s ability to spread, cause disease, evade immunity, or resist treatment.

The most controversial subset involves potential pandemic pathogensmicrobes that may be highly transmissible and capable of causing serious disease in humans. When research could make such pathogens more dangerous, the concern is obvious: a laboratory accident, theft, misuse, or publication of sensitive details could create risks that extend far beyond the lab. A mistake in a chemistry class may ruin a lab coat. A mistake involving a highly transmissible respiratory virus could ruin much more than laundry day.

That is why modern policy debates often avoid the loose phrase “gain-of-function” and use narrower terms such as “enhanced potential pandemic pathogens,” “pathogens with enhanced pandemic potential,” or “dual use research of concern.” These terms may sound like they were assembled by a committee trapped in a conference room with bad coffee, but the goal is important: define the riskiest work precisely enough to regulate it without freezing beneficial science.

Why Scientists Pursue This Research

The strongest argument for high-risk pathogen research is not curiosity for curiosity’s sake. It is preparedness. Viruses evolve naturally. Influenza, coronaviruses, and other pathogens do not wait for humans to finish paperwork before changing. Scientists want to understand which mutations might make a virus more transmissible, more severe, or better able to escape existing vaccines and treatments. That knowledge can help guide surveillance, vaccine design, antiviral development, diagnostics, and public health planning.

1. Better surveillance

If researchers know which genetic changes are associated with dangerous traits, public health teams can watch for those changes in nature. This is especially important for viruses that circulate in animals and occasionally jump into humans. Surveillance is not glamorous. It is the scientific version of checking the smoke detector before the house smells funny.

2. Faster vaccine and drug development

Some experiments help researchers understand how pathogens interact with host cells or immune defenses. That information can point toward vaccine targets, therapeutic strategies, and diagnostic markers. Supporters argue that carefully controlled research can help society prepare for threats before they arrive at the emergency room.

3. Testing assumptions before nature does

Nature is the world’s largest and least regulated laboratory. It runs experiments constantly, without ethics forms or public comment periods. Scientists sometimes argue that controlled lab studies can reveal which evolutionary paths are plausible, helping us avoid being surprised later. That argument has weight. The problem is that “controlled” is doing a lot of work in that sentence.

Where the Hubris Begins

Hubris does not always look like a villain laughing over a bubbling flask. Usually, it looks like confidence. It sounds like, “We have protocols.” It says, “Our institution is different.” It wears a badge, attends a review meeting, and uses phrases like “robust mitigation strategy.”

Confidence is necessary in science. Without it, nobody would launch a clinical trial, design a vaccine, or spend three years studying a protein that behaves like a moody house cat. But confidence becomes dangerous when it stops asking, “What if we are wrong?” Gain-of-function debates are really debates about the limits of expertise. How much risk can a small group of specialists impose on a large public? Who gets to decide whether the benefits justify the hazards? How transparent should those decisions be? And what happens when the people making the decision also benefit from the research continuing?

That is the hubris problem. It is not that scientists are reckless as a class. Many are deeply cautious. It is that institutions can become overly comfortable with their own safeguards. They may assume that risk is manageable because it has been managed so far. But “nothing bad happened last time” is not a safety system. It is a sentence often spoken before the movie changes genre.

The H5N1 Controversy: A Case Study in Scientific Nerves

The modern gain-of-function debate gained public attention in the early 2010s when researchers studying H5N1 avian influenza reported experiments involving strains that could transmit between ferrets, a common model for human flu transmission. The work raised a brutal question: should scientists create or characterize a more transmissible version of a dangerous virus to understand pandemic risk?

Supporters argued that the research helped identify warning signs that could appear in nature. Critics argued that the work itself created a hazard. The publication debate became nearly as controversial as the experiments. Some experts worried that detailed methods could be misused. Others warned that restricting publication would weaken scientific openness and slow preparedness.

The controversy forced governments, journals, funders, and scientists to confront a reality that had been quietly growing in the background: biology had become powerful enough that the line between knowledge and hazard was no longer theoretical. A paper could be a warning sign, a scientific resource, and a security concern all at once.

COVID-19 and the Collapse of Easy Trust

The COVID-19 pandemic intensified public interest in pathogen research. The origins of SARS-CoV-2 remain a subject of investigation and debate, and it is important not to replace uncertainty with a confident story simply because confident stories are easier to share online. What is clear is that the pandemic made the public far more aware of laboratory safety, international research collaborations, federal funding, and the challenges of oversight.

In the COVID era, many people heard the phrase “gain-of-function” for the first time through political arguments, cable news segments, congressional hearings, and social media threads written with the emotional restraint of a raccoon in a vending machine. The result was predictable: confusion. Some used the term broadly for almost any risky pathogen work. Others used it narrowly, according to specific policy definitions. The same experiment could be described differently depending on the speaker, the policy framework, and the political temperature of the room.

This definitional fog matters. Public trust depends on clear language. If agencies say research is not “gain-of-function” under one technical definition while critics use a broader everyday meaning, people hear evasion. Even when officials are being technically accurate, they may appear slippery. In public health, appearing slippery is almost as damaging as being slippery.

Oversight Has Improved, But It Is Still Catching Up

The United States has spent more than a decade revising oversight for risky pathogen research. After earlier controversies, federal policy moved through funding pauses, review frameworks, and evolving definitions. The 2017 P3CO framework focused on proposed research involving enhanced potential pandemic pathogens. In 2024, the federal government released a unified policy for oversight of dual use research of concern and pathogens with enhanced pandemic potential. In 2025, an executive action added new restrictions and called for changes around “dangerous gain-of-function” research.

That timeline shows progress, but it also shows a system that often reacts after controversy. Oversight has been improving, yet the biology keeps moving. Synthetic biology tools become cheaper. Viral databases grow. Artificial intelligence changes how researchers search, design, and analyze biological systems. International collaborations expand faster than domestic accountability mechanisms. The question is no longer only, “Can we regulate this one experiment?” It is, “Can governance keep up with an entire ecosystem of rapidly advancing life science?”

The transparency gap

One persistent concern is transparency. Risk-benefit reviews often happen inside agencies or institutions, with limited public explanation. Some confidentiality is understandable. Research proposals may contain sensitive details, proprietary information, or security-relevant methods. But secrecy has a cost. If the public cannot see how decisions are made, it may assume the worst. And once trust is gone, even good science has to climb uphill in wet shoes.

The accountability problem

Another issue is accountability. If a risky project is approved, who owns the risk? The principal investigator? The university? The funding agency? The review board? The journal? The contractor? The answer is often “all of the above,” which can become “none of the above” when something goes wrong. Clear responsibility should be part of any serious oversight system.

The Benefits Are Real, But So Are the Alternatives

A mature discussion must admit that high-risk pathogen research can produce valuable knowledge. It can clarify how pathogens evolve, help identify concerning mutations, improve animal models, and support medical countermeasures. Pretending there are no benefits is not responsible. It is just anti-science wearing a safety vest.

But pretending there are no alternatives is equally irresponsible. Safer approaches may include computational modeling, genomic surveillance, pseudovirus systems, non-replicating platforms, lower-risk surrogate organisms, improved field epidemiology, and better global data sharing. These tools are not always perfect substitutes. Sometimes they cannot answer the exact same question. But “not perfect” does not mean “not worth trying first.”

The ethical standard should be simple: the riskier the experiment, the stronger the burden of proof. Researchers should have to show why the question matters, why safer methods are insufficient, how risks will be reduced, who will monitor compliance, and how the public benefit will be measured. “Because it would be scientifically interesting” is not enough when the downside could be measured in hospital beds.

Risk Is Not Just a Technical Number

One mistake in the gain-of-function debate is treating risk as if it were only a mathematical problem. Yes, probability matters. Consequence matters. Biosafety level matters. Training, engineering controls, and incident reporting matter. But risk also has a social dimension.

A community may reasonably ask why it should accept danger from research it did not approve, cannot inspect, and may never benefit from directly. A taxpayer may ask why public money funds experiments whose review process is difficult to understand. A patient may ask whether delays caused by overregulation could cost lives. A scientist may ask whether fear-based policy will stop important research. These are not silly questions. They are the actual democratic terrain on which science operates.

That is why the “trust us” model is obsolete. Trust must be earned through clear standards, independent review, public explanation, incident transparency, and honest discussion of uncertainty. The public does not need every technical detail. It does need confidence that someone other than the grant applicant has looked hard at the risks and said, “Prove this is worth it.”

What a Humble Research System Would Look Like

A humble system would not ban every risky experiment, nor would it wave them through because a famous institution submitted polished paperwork. It would treat dangerous pathogen research as exceptional. It would make approvals rare, rigorous, and explainable.

1. Independent risk-benefit review

High-risk studies should be evaluated by experts who are not directly invested in the project’s success. Virologists are essential, but so are biosafety professionals, public health experts, ethicists, security specialists, and community representatives. A room full of brilliant people with the same incentives can still miss the obvious.

2. Stronger incident reporting

Laboratory accidents and near misses should be reported in ways that allow the research community to learn from them. Aviation became safer by studying failure obsessively. Biology should do the same. A near miss is a gift from reality. Ignoring it is rude.

3. Safer-methods-first requirements

Before approving work that could enhance a dangerous pathogen, reviewers should ask whether safer approaches can answer the question. If the answer is yes, the safer method should win. If the answer is no, the research team should explain why in plain language.

4. Better international standards

Pathogens do not respect national borders, and neither should biosafety expectations. International collaborations need enforceable standards, not vague assurances. If U.S. funds support work abroad, oversight should be strong enough to satisfy U.S. safety expectations and transparent enough to withstand public scrutiny.

5. Public communication that does not insult the public

People can handle complexity. What they dislike is being managed. Agencies and institutions should communicate uncertainty honestly, define terms clearly, and avoid the reflex to hide behind jargon. The public may not know every technical detail, but it can detect condescension from orbit.

Science Needs Ambition and Humility

The lesson is not that scientists should stop asking dangerous questions. Some dangerous questions matter. The lesson is that dangerous questions require a different moral posture. Ambition must come with restraint. Expertise must come with accountability. Innovation must come with guardrails strong enough to hold when enthusiasm gets heavy.

“We are not that great” should not be read as despair. It should be read as wisdom. We are smart, but not omniscient. Careful, but not flawless. Innovative, but not immune to incentives. Capable of extraordinary good, but also capable of building systems that assume luck is a policy.

Gain-of-function research highlights our hubris because it forces us to stare at the gap between what we can do and what we can responsibly govern. That gap is where accidents happen, trust erodes, and scientific legitimacy gets bruised. Closing it will require more than new acronyms. It will require a culture that treats humility not as a weakness, but as a safety feature.

Conclusion: The Point Is Not Fear, But Responsibility

The debate over gain-of-function research is often framed as science versus safety, but that is the wrong fight. The real goal is science with safety. Public health needs research. It also needs public trust, transparent oversight, and institutions brave enough to say no when the risk is too high or the benefit too vague.

Human progress has always depended on people willing to explore the unknown. But exploration is not the same as swagger. The best science does not say, “Relax, we have this.” It says, “Here is what we know, here is what we do not know, here is how we are reducing risk, and here is who will hold us accountable.” That kind of humility may not trend on social media, but it is exactly what high-consequence biology needs.

In the end, gain-of-function research is a mirror. It shows our brilliance, our anxiety, our politics, our ambition, and our blind spots. It asks whether we can become wise enough to manage the power we have created. The answer is not guaranteed. But admitting “we are not that great” may be the first truly great step.

Experience Notes: What This Debate Teaches Beyond the Laboratory

One of the most useful ways to understand gain-of-function research is to step outside the lab and look at ordinary human behavior. Most major mistakes do not begin with someone saying, “Let us make the worst possible choice.” They begin with small assumptions. The deadline is tight, but manageable. The checklist is familiar, so maybe it can be rushed. The expert has done this before, so maybe a second opinion is unnecessary. The institution has a good reputation, so maybe its internal process is enough. The danger is not cartoon recklessness. The danger is comfort.

In science communication, the same pattern appears constantly. People want certainty, but responsible experts often have to offer probabilities. People want simple villains, but real systems fail through layers: incentives, ambiguity, weak reporting, underfunded safety programs, political pressure, and plain old human fatigue. When discussing risky pathogen research, the public conversation often jumps straight to accusation or defense. That may be emotionally satisfying, but it does not fix the system. A better conversation asks how decisions were made, who reviewed them, what alternatives were considered, what safeguards existed, and what would happen if the assumptions proved wrong.

The topic also teaches a lesson about language. Technical definitions may be accurate inside agencies, but public meaning matters. If officials use a narrow definition of gain-of-function while the public uses a broader one, both sides can talk past each other. The result is suspicion. Clear communication is not cosmetic. It is a core safety tool. When people understand what is being studied, why it matters, and how risks are controlled, they are more likely to trust the processeven when they disagree with a decision.

Another practical lesson is that humility should be designed into systems, not merely praised in speeches. A humble system creates friction before high-risk choices. It invites criticism early. It funds biosafety as seriously as discovery. It rewards researchers for reporting near misses, not hiding them. It uses independent review because even brilliant people are better when someone is allowed to challenge them. It asks, again and again, whether a safer method could answer the same question.

Finally, this debate reminds us that public trust is slow to earn and easy to lose. Once people believe experts are minimizing risk, even accurate statements sound suspicious. That is why the strongest defense of science is not arrogance. It is accountability. The world needs bold researchers, but it also needs researchers and institutions willing to say, “This is too risky,” “We do not know yet,” and “The public deserves a clearer answer.” In high-stakes biology, humility is not a decorative virtue. It is protective equipment.